From Vetter Pharma International GmbH
Tuesday, July 05, 2022 10:00 am MYT
Vetter Development Services Rankweil is expanding
- The next milestone for site development has been reached
- Received positive feedback from audits with more audits scheduled
- Planned expansions will help meet increased customer demand
RAVENSBURG, GERMANY AND RANKWEIL, AUSTRIA – Media OutReach – July 5, 2022 – With the realization of the first successful customer bottlings cousina leading global contract engineering and manufacturing company (CDMO), has achieved another milestone in its new clinical manufacturing facility in Rankweil, Austria. Further batches are already planned, further customer projects in the business pipeline. In addition, the site will be expanded in order to optimize processes and increase production capacities.
Vetter acquired the Rankweil facility in mid-2020 to meet growing customer demand for complex fill-and-finish solutions in early stages of drug development and to act as a European counterpart to the company’s clinical manufacturing Location near Chicago in the USA. Within a year of purchase, the site was adapted to Vetter’s high quality standards and integrated. In December 2021, the responsible national regulatory authority successfully completed the cGMP inspection Austrian Agency for Health and Food Safety (AGES) has been achieved, enabling the facility to support clinical development projects of global pharmaceutical and biotech companies.
“We have been very focused on achieving the strategic integration of the site,” said Dr. Martin Schwab, Site Manager Austria. “With hard work and focus, we have managed to quickly make the site fully operational and are already planning expansion and further development.” In order to offer customers additional production capacities, a second autoclave and another washing machine for material processing will be implemented in the coming months as well as an adaptation of the existing lyophilizer to the Ravensburger site in order to enable an optimized coordination of systems and processes Transition from clinical to commercial Production at Vetter.
Andrea Wesp, Vice President New Business Development, added: “Our intention is to support global customer projects as best we can by offering a flexible and holistic service portfolio for clinical manufacturing. The positive feedback we have received so far from customers who have already visited our Rankweil site is proof not only that we are meeting their needs, but that we have achieved an important step in our business strategy.”
Here you will find the Vetter press kit and further background information here
Headquartered in Ravensburg, Germany, Vetter is a family-run, world-leading contract engineering and manufacturing company (CDMO) with manufacturing facilities in Germany, Austria and the United States. Currently employs more than 5,700 people worldwidethe company has many years of experience in supporting small and large biotechnology and pharmaceutical customers. cousin Services ranging from early stage development support including clinical manufacturingto commercial supply and numerous packaging solutions for vials, syringes and cartridges. As a leading solutions provider, Vetter recognizes its responsibility to support its customers’ needs by developing devices that contribute to increased patient safety, comfort and improved compliance. It is also very important social responsibility including environmental protection and sustainability. Learn more about cousin below www.vetter-pharma.com.